PA8530701A1 - Combinaciones farmaceuticas - Google Patents

Combinaciones farmaceuticas

Info

Publication number
PA8530701A1
PA8530701A1 PA20018530701A PA8530701A PA8530701A1 PA 8530701 A1 PA8530701 A1 PA 8530701A1 PA 20018530701 A PA20018530701 A PA 20018530701A PA 8530701 A PA8530701 A PA 8530701A PA 8530701 A1 PA8530701 A1 PA 8530701A1
Authority
PA
Panama
Prior art keywords
pharmaceutical combinations
thrombolitical
neutrrophiles
fibrinolitical
favorates
Prior art date
Application number
PA20018530701A
Other languages
English (en)
Inventor
Christopher John Brearley
Paul Butler
Suresh Babubhai Chahwala
Michael Chopp
Michael Krams
Michael Looby
Fiona Macintyre
Andrew Brian Mcelroy
Aileen Dorothy Mcharg
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8530701A1 publication Critical patent/PA8530701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE, ENTRE OTROS, A METODOS PARA TRATAR CONDICIONES PATOFISIOLOGICAS QUE IMPLICAN NEUTROFILOS, QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE NECESITE TAL TRATAMIENTO UNA TERAPIA DE COMBINACION QUE COMPRENDE AL MENOS UN FACTOR INHIBIDOR DE LOS NEUTROFILOS (NIF) Y AL MENOS OTRO AGENTE QUE PROTEGE A LAS NEURONAS DE LA AGRESION TOXICA, INHIBE LA REACCION INFLAMATORIA DESPUES DE UNA LESION CEREBRAL O FAVORECE LA REPERFUSION CEREBRAL (ESTO ES, AGENTES NEUROPROTECTORES O TROMBOLITICOS/FIBRINOLITICOS), O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES.
PA20018530701A 2000-10-17 2001-10-17 Combinaciones farmaceuticas PA8530701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025473.0A GB0025473D0 (en) 2000-10-17 2000-10-17 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
PA8530701A1 true PA8530701A1 (es) 2003-06-30

Family

ID=9901490

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018530701A PA8530701A1 (es) 2000-10-17 2001-10-17 Combinaciones farmaceuticas

Country Status (13)

Country Link
US (1) US20020098179A1 (es)
AP (1) AP2001002295A0 (es)
AR (1) AR034698A1 (es)
AU (1) AU2002210795A1 (es)
DO (1) DOP2001000266A (es)
GB (1) GB0025473D0 (es)
GT (1) GT200100207A (es)
HN (1) HN2001000232A (es)
PA (1) PA8530701A1 (es)
PE (1) PE20020536A1 (es)
TN (1) TNSN01142A1 (es)
UY (1) UY26969A1 (es)
WO (1) WO2002032446A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20030219431A1 (en) * 2002-05-24 2003-11-27 Empire Pharmaceuticals, Inc. Treatment of neuronal and neurological damage associated with spinal cord injury
CN1310949C (zh) * 2003-01-13 2007-04-18 重庆富进生物医药有限公司 具有抑制白细胞功能和凝血酶活性的双功能嵌合蛋白
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
US20070167419A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
AU2006335153B2 (en) 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
JP2010532383A (ja) * 2007-07-02 2010-10-07 エッセンシャリス，インク． カリウムａｔｐチャネル開口薬の塩およびその使用
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
JP6005514B2 (ja) 2009-06-10 2016-10-12 ノノ インコーポレイテッド 神経疾患の治療のためのモデル系及び治療計画
US10064910B2 (en) * 2011-06-24 2018-09-04 Nono Inc. Combination therapy for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2016073514A2 (en) 2014-11-03 2016-05-12 Thrombolytic Science, Llc Methods and compositions for safe and effective thrombolysis
US10336827B2 (en) 2015-10-29 2019-07-02 Wayne State University Compositions and methods to treat solid tumors
EP3411022B1 (en) * 2016-02-01 2021-09-15 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
CN116669757A (zh) * 2020-11-17 2023-08-29 泰伦基国际有限公司 一种提高bdnf水平的方法和药物
WO2022261282A1 (en) * 2021-06-09 2022-12-15 Proniras Corporation Methods of treating or preventing conditions associated with opiate withdrawal or opiate relapse

Also Published As

Publication number Publication date
PE20020536A1 (es) 2002-06-20
UY26969A1 (es) 2002-06-20
HN2001000232A (es) 2002-04-22
AP2001002295A0 (en) 2001-12-31
DOP2001000266A (es) 2002-05-31
TNSN01142A1 (fr) 2005-11-10
AU2002210795A1 (en) 2002-04-29
US20020098179A1 (en) 2002-07-25
WO2002032446A3 (en) 2002-07-11
GB0025473D0 (en) 2000-11-29
AR034698A1 (es) 2004-03-17
WO2002032446A2 (en) 2002-04-25
GT200100207A (es) 2002-08-19

Similar Documents

Publication Publication Date Title
PA8530701A1 (es) Combinaciones farmaceuticas
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
PA8568701A1 (es) Compuestos que modulan la actividad de ppar
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
PA8567801A1 (es) Compuestos que modulan la actividad de ppar
CR7330A (es) Procedimiento para tratar enfermedades neovasculares oculares
DE60035870D1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
ECSP066516A (es) Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos
NI200300039A (es) Compuestos que modulan la actividad de ppar.
BRPI0417006A (pt) administração intraóssea local de agentes de formação de osso e agentes anti-reabsorção e dispositivos para a mesma
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
CU23251A3 (es) Formulaciones liquidas estables de toxina botulinica
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
ES2183817T3 (es) Inibidores de proteasas de parasatiso metazoarios.
UY29723A1 (es) Uso de arilanilidas para tratamiento de semillas
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
CL2004001425A1 (es) Compuesto derivados de bencilamida; composicion farmaceutica que lo comprende; uso para tratar o prevenir la infeccion por papilomavirus; y kit farmaceutico que lo contiene.
BR112023022514A2 (pt) Oligonucleotídeos antissenso e seu uso para tratamento de distúrbios neurodegenerativos
UY27316A1 (es) Derivados ácidos de azol sustituidos, útiles como agentes antidiabéticos y antiobesidad y método
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares